Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives

Kotla, Niranjan G.; Rana, Shubhasmin; Sivaraman, Gandhi; Sunnapu, Omprakash; Vemula, Praveen Kumar; Pandit, Abhay; Rochev, Yury

doi:10.1016/j.addr.2018.06.021

Cited by 165 publications

(101 citation statements)

References 140 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…These systems are dependent on the specific enzyme activity of the colonic bacteria and the polymers degradable by colonic microorganisms. Particularly, polysaccharides such as pectin, guar gum, inulin, and chitosan have been used in colon-targeted drug delivery systems, because they can retain their integrity in the upper GI tract but are metabolized by colonic microflora to release the entrapped drug [55]. Recently, new polysaccharides including arabinoxylans and agave fructans are also being explored for colonic drug delivery systems [56,57].…”

Section: Polysaccharide-based Systemsmentioning

confidence: 99%

Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements

et al. 2020

View full text Add to dashboard Cite

Colon targeted drug delivery systems have gained a great deal of attention as potential carriers for the local treatment of colonic diseases with reduced systemic side effects and also for the enhanced oral delivery of various therapeutics vulnerable to acidic and enzymatic degradation in the upper gastrointestinal tract. In recent years, the global pharmaceutical market for biologics has grown, and increasing demand for a more patient-friendly drug administration system highlights the importance of colonic drug delivery as a noninvasive delivery approach for macromolecules. Colon-targeted drug delivery systems for macromolecules can provide therapeutic benefits including better patient compliance (because they are pain-free and can be self-administered) and lower costs. Therefore, to achieve more efficient colonic drug delivery for local or systemic drug effects, various strategies have been explored including pH-dependent systems, enzyme-triggered systems, receptor-mediated systems, and magnetically-driven systems. In this review, recent advancements in various approaches for designing colon targeted drug delivery systems and their pharmaceutical applications are covered with a particular emphasis on formulation technologies.

show abstract

Section: Polysaccharide-based Systemsmentioning

confidence: 99%

Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[13,14] A recent study revealed the potential of Ac2-26 for the treatment of colitis after intraperitoneal or intramucosal injection of Ac2-26 in nanoparticles (NPs). [16][17][18][19][20][21] However, there are still tremendous challenges in the design and development of translational nanovehicles for oral delivery of macromolecular therapeutics, [16,[22][23][24][25] although different nanotherapies have been developed for targeted treatment of IBD. On the other hand, patient-friendly oral delivery is highly preferred for treatment of gastrointestinal and chronic diseases, owing to its convenience, high patient compliance, desirable cost-effectiveness, and good safety profile.…”

Section: Introductionmentioning

confidence: 99%

A Proresolving Peptide Nanotherapy for Site‐Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota

et al. 2019

View full text Add to dashboard Cite

The incidence and prevalence of inflammatory bowel disease (IBD) increases steadily worldwide. There is an urgent need for effective and safe IBD therapies. Accelerated resolution of inflammation is a new strategy for the management of inflammatory diseases. For effective and safe IBD treatment, herein a smart nanotherapy (i.e. oxidation‐responsive nanoparticles containing a proresolving annexin A1‐mimetic peptide Ac2‐26, defined as AON) is developed, which can release packaged Ac2‐26, in response to highly expressed reactive oxygen species (ROS) at diseased sites. AON effectively protects Ac2‐26 from degradation in the enzyme‐rich environment of the gastrointestinal tract. By delivering this nanotherapy to the inflamed colons of mice with IBD, site‐specific release and accumulation of Ac2‐26 in response to high levels of ROS at the inflammatory sites are achieved. Mechanistically, the Ac2‐26‐containing, oxidation‐labile nanotherapy AON effectively decreases the expression of proinflammatory mediators, attenuates trafficking and infiltration of inflammatory cells, promotes efferocytosis of apoptotic neutrophils, and increases phenotypic switching of macrophages. Therapeutically, AON reduces symptoms of inflammation, accelerates intestinal mucosal wound healing, reshapes the gut microbiota composition, and increases short‐chain fatty acid production. Additionally, oral delivery of this nanomedicine shows excellent safety profile in a mouse model, conferring the confidence for further development of a targeted precision therapy for IBD and other inflammatory diseases.

show abstract

“…Most recently, our group has developed a series of ROSresponsive materials by conjugating phenylboronic acid pinacol ester (PBAP) onto β-cyclodextrin (β-CD), a cyclic oligosaccharide with excellent in vivo safety (Zhang and Ma, 2013). The obtained ROS-responsive materials can be used to construct nanoparticles for site-specific delivery and inflammation-responsive release of different therapeutics (Juni et al, 2013;Lamprecht, 2015;Zhang Q. et al, 2016;Alaarg et al, 2017;Kotla et al, 2019). Interestingly, nanoparticles based on PBAP-conjugated cyclodextrin materials can effectively eliminate H 2 O 2 , thereby inhibiting inflammatory responses and oxidative stress in stimulated macrophages .…”

Section: Nanoparticles Derived From Functional Cyclodextrin Materialsmentioning

confidence: 99%

“…Unfortunately, non-specific distribution and low retention of these compounds often results in multiple side effects. So far, a number of studies have reported the construction of orally available antioxidant nanoparticles for IBD therapy with high inflamed colon retention and therapeutic effects (Vong et al, 2012;Lamprecht, 2015;Alaarg et al, 2017;Bak et al, 2018;Gou et al, 2019;Kotla et al, 2019;Li S. et al, 2019;Schilrreff et al, 2019).…”

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Chen

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Reactive oxygen species (ROS) are essential in regulating various physiological functions. However, overproduction of ROS is implicated in the pathogenesis of various inflammatory diseases. Antioxidant therapy has thus represented an effective strategy for the treatment of oxidative stress relevant inflammatory diseases. Conventional anti-oxidative agents showed limited in vivo effects owing to their non-specific distribution and low retention in disease sites. Over the past decades, significant achievements have been made in the development of antioxidant nanotherapies that exhibit multiple advantages such as excellent pharmacokinetics, stable anti-oxidative activity, and intrinsic ROS-scavenging properties. This review provides a comprehensive overview on recent advances in antioxidant nanotherapies, including ROS-scavenging inorganic nanoparticles, organic nanoparticles with intrinsic antioxidant activity, and drug-loaded anti-oxidant nanoparticles. We highlight the biomedical applications of antioxidant nanotherapies in the treatment of different inflammatory diseases, with an emphasis on inflammatory bowel disease, cardiovascular disease, and brain diseases. Current challenges and future perspectives to promote clinical translation of antioxidant nanotherapies are also briefly discussed.

show abstract

Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives

Cited by 165 publications

References 140 publications

Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements

Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements

A Proresolving Peptide Nanotherapy for Site‐Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Contact Info

Product

Resources

About